GAGregory L. Adams

Gregory L. Adams

*This is an algorithmically generated author record based on publicly available information.

Gregory L. Adams has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Activity Refinement and Property Assessment of Peptidomimetics with Potent Antimalarial Activity That Target Plasmepsin V

    by Gregory L. Adams, Madeline G. Dans, Qingmiao Zhou, Wenyin Su, Anna Ngo, Kate E. Jarman, Maria V. Fawaz, Michael J. Kelly, John A. McCauley, David B. Olsen, et al.

    Plasmepsin V is an essential aspartyl protease that cleaves the Plasmodium export element in proteins targeted for export from Plasmodium parasites into the host red blood cell. Substrate-mimicking peptidomimetics have been developed that potently inhibit plasmepsin V but show modest parasite activity. To advance these inhibitors, we optimized their potency by introducing a 2-chloro aryl group at P2 and an N-terminal sulfonamide that yielded WM960, which showed markedly improved plasmepsin V inhibition while retaining high selectivity over plasmepsin IX and X and human aspartyl proteases. WM960 also demonstrated enhanced activity against asexual blood-stage parasites and effectively suppressed protein export. However, WM960 displayed low metabolic stability and limited systemic exposure in mice, highlighting the need to improve pharmacokinetic properties in future development of peptidomimetic plasmepsin V targeted antimalarials.

  • PepSeA: Peptide Sequence Alignment and Visualization Tools to Enable Lead Optimization

    by Javier L. Baylon, Oleg Ursu, Anja Muzdalo, Anne Mai Wassermann, Gregory L. Adams, Martin Spale, Petr Mejzlik, Anna Gromek, Viktor Pisarenko, Dzianis Hancharyk, et al.

    Therapeutic peptides offer potential advantages over small molecules in terms of selectivity, affinity, and their ability to target "undruggable" proteins that are associated with a wide range of pathologies. Despite their importance, current molecular design capabilities that inform medicinal chemistry decisions on peptide programs are limited. More specifically, there are unmet needs for structure-activity relationship (SAR) analysis and visualization of linear, cyclic, and cross-linked peptides containing non-natural motifs, which are widely used in drug discovery. To bridge this gap, we developed PepSeA (Peptide Sequence Alignment and Visualization), an open-source, freely available package of sequence-based tools (https://github.com/Merck/PepSeA). PepSeA enables multiple sequence alignment of non-natural amino acids and enhanced visualization with the hierarchical editing language for macromolecules (HELM). Via stepwise SAR analysis of a ChEMBL peptide data set, we demonstrate the utility of PepSeA to accelerate decision making in lead optimization campaigns in pharmaceutical setting. PepSeA represents an initial attempt to expand cheminformatics capabilities for therapeutic peptides and to enable rapid and more efficient design-make-test cycles.


  • Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Nav1.7 for the Treatment of Pain

    by Gregory L. Adams, Parul S. Pall, Steven M. Grauer, Xiaoping Zhou, Jeanine E. Ballard, Marissa Vavrek, Richard L. Kraus, Pierre Morissette, Nianyu Li, Stefania Colarusso, et al.

    Inhibitor cystine knot peptides, derived from venom, have evolved to block ion channel function but are often toxic when dosed at pharmacologically relevant levels in vivo. The article describes the design of analogues of ProTx-II that safely display systemic in vivo blocking of Nav1.7, resulting in a latency of response to thermal stimuli in rodents. The new designs achieve a better in vivo profile by improving ion channel selectivity and limiting the ability of the peptides to cause mast cell degranulation. The design rationale, structural modeling, in vitro profiles, and rat tail flick outcomes are disclosed and discussed.


  • Discovery of Chromane Propionic Acid Analogues as Selective Agonists of GPR120 with in Vivo Activity in Rodents

    by Gregory L. Adams, Francisco Velazquez, Charles Jayne, Unmesh Shah, Shouwu Miao, Eric R. Ashley, Maria Madeira, Taro E. Akiyama, Jerry Di Salvo, Takao Suzuki, et al.

    GPR120 (FFAR4) is a fatty acid sensing G protein coupled receptor (GPCR) that has been identified as a target for possible treatment of type 2 diabetes. A selective activator of GPR120 containing a chromane scaffold has been designed, synthesized, and evaluated in vivo. Results of these efforts suggest that chromane propionic acid 18 is a suitable tool molecule for further animal studies. Compound 18 is selective over the closely related target GPR40 (FFAR1), has a clean off-target profile, demonstrates suitable pharmacokinetic properties, and has been evaluated in wild-type/knockout GPR120 mouse oGTT studies.